Director buying at Spectral Medical (EDT)

Director buying at Spectral Medical (T:EDT)

Kevin Arnold Giese, a Director, acquired 400,000 Common Shares on a direct ownership basis at a price of $0.300 through a prospectus or prospectus exempt offering on April 20th, 2018. The insider also acquired 200,000 Warrants with an exercise price of $0.450 April 20, 2021. This represents a $120,000 investment into the company's shares and an account share holdings change of 13.7%.

Spectral Medical is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.

Spectral Medical Inc., formerly Spectral Diagnostics Inc., is a therapeutic development company. The Company is focused on the development and commercialization of a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) and the Toraymyxin (PMX) therapeutic. The Company also manufactures and sells certain reagents. The Company develops biochemical markers for the clinical syndrome known as septic shock. PMX is a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. The Company develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies through non-exclusive license and supply agreements.